Figures & data
Figure 1. EGFR mutational status of lung adenocarcinoma (LUAD). Abbreviation: EGFR-mt, EGFR mutation adenocarcinoma; EGFR-wd, EGFR wild type adenocarcinoma.
![Figure 1. EGFR mutational status of lung adenocarcinoma (LUAD). Abbreviation: EGFR-mt, EGFR mutation adenocarcinoma; EGFR-wd, EGFR wild type adenocarcinoma.](/cms/asset/15efdeca-bac1-449d-88b7-84f5d57a4b65/iivs_a_2301081_f0001_c.jpg)
Table 1. The clinicopathological features of 89 LUAD patients.
Figure 2. Different expressions of HIF-1α and PKM2 in normal lung tissue (NLT) and lung adenocarcinoma (LUAD).
![Figure 2. Different expressions of HIF-1α and PKM2 in normal lung tissue (NLT) and lung adenocarcinoma (LUAD).](/cms/asset/f2b1517a-0a97-4e03-a92d-9448d4da5593/iivs_a_2301081_f0002_c.jpg)
Table 2. Expressions of HIF-1α and PKM2 in normal lung tissue and lung adenocarcinoma.
Table 3. Relationship between the expression of HIF-1α and PKM2 in lung adenocarcinoma.
Table 4. Relationships of HIF-1α/PKM2 feedback loop proteins with clinical pathological characteristics in adenocarcinomas of lung.
Figure 3. Different expressions of HIF-1α and PKM2 in EGFR wild type (EGFR-wd) and EGFR mutation (EGFR-mt) lung adenocarcinomas.
![Figure 3. Different expressions of HIF-1α and PKM2 in EGFR wild type (EGFR-wd) and EGFR mutation (EGFR-mt) lung adenocarcinomas.](/cms/asset/2a838cc8-4981-47b6-92af-7e2465231934/iivs_a_2301081_f0003_c.jpg)
Table 5. HIF-1α and PKM2 protein expressions in EGFR wild-type versus EGFR-mutated lung adenocarcinoma.
Table 6. Relationship between the expression of HIF-1α and PKM2 protein in EGFR wild-type versus EGFR-mutated lung adenocarcinoma.
Table 7. Relationships of HIF-1α/PKM2 feedback loop proteins with clinical pathological characteristics in EGFR wild-type versus EGFR-mutated lung adenocarcinoma.